Related Experiment Video
Updated: Feb 25, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5
Franziska Jönsson1, Florian Kreppel2
1Chair of Biochemistry and Molecular Medicine, Center for Biomedical Research and Education (ZBAF), Witten/Herdecke University (UW/H), Stockumer Straße 10, 58453, Witten, Germany.
Abstract:
Currently, virus-based vectors, namely derivatives of the adenovirus, are frequently used in a wide variety of ex vivo or local gene therapeutic applications. However, the efficacy of virus-based vectors in systemic applications is presently still extremely limited. Complex interactions of the various vector types with the patient's organism hinder successful vector deployment. Exemplary, here we summarize barriers to systemic application of Adenovirus-based vectors leading either to acute toxic effects or rapid vector neutralization and discuss strategies to overcome these barriers aiming to develop more efficient vector types.
Related Concept Videos
Gene Therapy
Microorganisms in Medicine and Therapeutics

